Thermo Fisher, NanoPin partner on infectious disease workflows

By staff writers

February 14, 2020 -- Thermo Fisher Scientific is partnering with infectious disease diagnostic company NanoPin Technologies to develop workflows for liquid chromatography-mass spectrometry (LC-MS).

The partnership will utilize Thermo Fisher's LC-MS technology and NanoPin's diagnostic platform to identify disease-related antigens from patient blood samples, Thermo Fisher said.

The goal is for the companies' combined technologies to lead to the development of sensitive clinical assays for infectious diseases, ultimately reducing time to results.

Mass spectrometry brings speed, accuracy, specificity to labs
For years, mass spectrometry found extensive use as a valuable analytical tool in industries ranging from chemical processing to drug discovery and development....
Thermo Fisher posts 5% higher sales in Q4
Lab and scientific instruments manufacturer Thermo Fisher Scientific posted revenues for the fourth quarter of 2019 that were up 4.9%, while net income...
LabCorp adopts Thermo Fisher NGS for companion diagnostics
LabCorp announced that it will adopt Thermo Fisher Scientific's Ion Torrent Genexus next-generation sequencing (NGS) system and Oncomine precision assay...
Thermo Fisher teams with Owlstone on breath tests
Thermo Fisher Scientific is working with Owlstone Medical to develop noninvasive breath sample tests in a collaboration that will include the discovery...
Thermo Fisher seals companion test deal with Lilly
Thermo Fisher Scientific has signed an agreement to develop its Oncomine Dx for use as a companion test with Lilly's LOXO-292 drug in non-small cell lung...

Copyright © 2020

Last Updated np 2/13/2020 5:27:28 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.